中华眼底病杂志

中华眼底病杂志

再度审视激光光凝在视网膜血管疾病治疗中的价值

查看全文

黄斑水肿是引起以糖尿病视网膜病变和视网膜静脉阻塞为代表的视网膜血管疾病患者视力下降的常见原因。激光光凝在过去几十年中一直是该类疾病的主要治疗方法。近年来随着抗血管内皮生长因子药物和类固醇激素缓释剂等新型眼内药物的应用,使得糖尿病黄斑水肿和继发于视网膜静脉阻塞的黄斑水肿得以较好的控制,导致传统激光光凝治疗适应证范围逐渐缩小。但值得注意的是,目前眼内药物的治疗存在可能的风险和并发症,其治疗效果和安全性还需要更长期的验证,仍无法完全替代激光光凝。新型激光的出现,在同样有效的治疗基础上,更有可能减少视网膜损伤。因而,应再度审视激光光凝在视网膜血管疾病治疗中的价值,合理选择适应证,提高其安全性和有效性。

Macular edema is a common cause of visual loss in patients with retinal vascular diseases represented by diabetic retinopathy and retinal vein occlusion. Laser photocoagulation has been the main treatment for this kind of diseases for decades. With the advent of antagonist of vascular endothelial growth factor and dexamethasone implant, diabetic macular edema and macular edema secondary to retinal vein occlusion have been well controlled; the use of laser therapy is decreasing. However, considering possible risks and complications, lack of extended inspection of efficacy and safety of intravitreal pharmacotherapy, laser therapy cannot be replaced by now. Therefore, the efficacy and safety of laser therapy will improve by sober realization of role of photocoagulation and proper selection of treatment indication.

关键词: 黄斑水肿/治疗; 糖尿病视网膜病变/治疗; 视网膜静脉闭塞/治疗; 激光凝固术; 述评

Key words: Macular edema/therapy; Diabetic retinopathy/therapy; Retinal vein occlusion/therapy; Laser coagulation; Editorial

引用本文: 王海燕, 王雨生. 再度审视激光光凝在视网膜血管疾病治疗中的价值. 中华眼底病杂志, 2018, 34(5): 424-428. doi: 10.3760/cma.j.issn.1005-1015.2018.05.002 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
1. Hayreh SS. Ocular vascular occlusive disorders: natural history of visual outcome[J]. Prog Retin Eye Res, 2014, 41: 1-25. DOI: 10.1016/j.preteyeres.2014.04.001.
2. Tan GS, Cheung N, Simó R, et al. Diabetic macular oedema[J]. Lancet Diabetes Endocrinol, 2017, 5(2): 143-155. DOI: 10.1016/S2213-8587(16)30052-3.
3. Khayat M, Williams M, Lois N. Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion[J/OL]. Surv Ophthalmol, 2018, 2018:E1[2018-04-27] . https://linkinghub.elsevier.com/retrieve/pii/S0039-6257(17)30113-3. DOI: 10.1016/j.survophthal.2018.04.005.[published online ahead of print].
4. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy[J]. N Engl J Med, 2012, 366: 1227-1239. DOI: 10.1056/NEJMra1005073.
5. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8[J]. Ophthalmology, 1981, 88(7): 583-600.
6. Central Vein Occlusion Study Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion: the Central Vein Occlusion Study Group N report[J]. Ophthalmology, 1995, 102(10): 1434-1444.
7. Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion[J]. Am J Ophthalmol, 1984, 98(3): 271-282.
8. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. ETDRS report number 1[J]. Arch Ophthalmol, 1985, 103(12): 1796-1806.
9. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase Ⅲ randomized trials: RISE and RIDE[J]. Ophthalmology, 2012, 119(4): 789-801. DOI: 10.1016/j.ophtha.2011.12.039.
10. Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies[J]. Ophthalmology, 2016, 123(11): 2376-2385. DOI: 10.1016/j.ophtha.2016.07.032.
11. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase Ⅲ study[J]. Ophthalmology, 2011, 118(10): 2041-2049. DOI: 10.1016/j.ophtha.2011.02.038.
12. Pearson PA, Comstock TL, Ip M, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial[J]. Ophthalmology, 2011, 118(8): 1580-1587. DOI: 10.1016/j.ophtha.2011.02.048.
13. Li X, Wang N, Liang X, et al. Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study[J]. Graefe’s Arch Clin Exp Ophthalmol, 2018, 256(1): 59-69. DOI: 10.1007/s00417-017-3831-6.
14. Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema[J]. Ophthalmology, 2014, 121(10): 1904-1914. DOI: 10.1016/j.ophtha.2014.04.024.
15. Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings[J/OL]. Ophthalmology, 2018, 2018:E1[2018-05-24] . https://linkinghub.elsevier.com/retrieve/pii/S0161-6420(17)33523-6. DOI: 10.1016/j.ophtha.2018.04.007.[published online ahead of print].
16. Pulido JS, Flaxel CJ, Adelman RA, et al. Retinal vein occlusions preferred practice in pattern (®) guidelines[J]. Ophthalmology, 2016, 123(1): 182-208. DOI: 10.1016/j.ophtha.2015.10.045.
17. Tang J, Kern TS. Inflammation in diabetic retinopathy[J]. Prog Retin Eye Res, 2011, 30(5): 343-358. DOI: 10.1016/j.preteyeres.2011.05.002.
18. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders[J]. N Engl J Med, 1994, 331(22): 1480-1487.
19. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the european society of retina specialists (EURETINA)[J]. Ophthalmologica, 2017, 237(4): 185-222. DOI: 10.1159/000458539.
20. Callanan DG, Gupta S, Boyer DS, et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema[J]. Ophthalmology, 2013, 120(9): 1843-1851. DOI: 10.1016/j.ophtha.2013.02.018.
21. Lang GE, Berta A, Eldem BM, et al. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study[J].Ophthalmology, 2013, 120(10): 2004-2012. DOI: 10.1016/j.ophtha.2013.02.019.
22. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema[J]. Ophthalmology, 2010, 117(6): 1064-1077. DOI: 10.1016/j.ophtha.2010.02.031.
23. Wessel MM, Nair N, Aaker GD, et al. Peripheral retinal ischemia, as evaluated by ultra-widefield fluorescein angiography, is associated with diabetic macular oedema[J]. Br J Ophthalmol, 2012, 96(5): 694-698. DOI: 10.1136/bjophthalmol-2011-300774.
24. Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report[J]. Ophthalmology, 1995, 102(10): 1425-1433.
25. Berger AR, Cruess AF, Altomare F, et al. Optimal treatment of retinal vein occlusion: canadian expert consensus[J]. Ophthalmologica, 2015, 234(1): 6-25. DOI: 10.1159/000381357.
26. Rehak M, Tilgner E, Franke A, et al. Early peripheral laser photocoagulation of nonperfused retina improves vision in patients with central retinal vein occlusion (results of a proof of concept study)[J]. Graefe’s Arch Clin Exp Ophthalmol, 2014, 252(5): 745-752. DOI: 10.1007/s00417-013-2528-8.
27. Campochiaro PA, Heier JS, Feiner L, et al. BRAVO investigators: ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase Ⅲstudy[J]. Ophthalmology, 2010, 117(6): 1102-1112. DOI: 10.1016/j.ophtha.2010.02.021.
28. Azad R, Vivek K, Sharma Y, et al. Ranibizumab as an adjunct to laser for macular edema secondary to branch retinal vein occlusion[J]. Indian J Ophthalmol, 2012, 60(4): 263-266. DOI: 10.4103/0301-4738.98701.
29. Donati S, Barosi P, Bianchi M, et al. Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion[J]. Eur J Ophthalmol, 2012, 22(4): 607-614. DOI: 10.5301/ejo.5000085.
30. Reddy RK, Pieramici DJ, Gune S, et al. Efficacy of ranibizumab in eyes with diabetic macular edema and macular nonperfusion in RIDE and RISE[J/OL]. Ophthalmology, 2018, 2018:E1[2018-05-08]. https://linkinghub.elsevier.com/retrieve/pii/S0161-6420(17)33607-2. DOI: 10.1016/j.ophtha.2018.04.002.[published online ahead of print].
31. Larsen M, Waldstein SM, Boscia F, et al. Individualized ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: twelve-month results of the CRYSTAL study[J]. Ophthalmology, 2016, 123(5): 1101-1111. DOI: 10.1016/j.ophtha.2016.01.011.
32. Campochiaro PA, Bhisitkul RB, Shapiro H, et al. Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion[J]. Ophthalmology, 2013, 120(4): 795-802. DOI: 10.1016/j.ophtha.2012.09.032.
33. Campochiaro PA, Wykoff CC, Shapiro H, et al. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema[J]. Ophthalmology, 2014, 121(9): 1783-1789. DOI: 10.1016/j.ophtha.2014.03.021.
34. Mir TA, Kherani S, Hafiz G, et al. Changes in retinal nonperfusion associated with suppression of vascular endothelial growth factor in retinal vein occlusion[J]. Ophthalmology, 2016, 123(3): 625-634. DOI: 10.1016/j.ophtha.2015.10.030.
35. Sophie R, Hafiz G, Scott AW, et al. Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion[J]. Am J Ophthalmol, 2013, 156(4): 693-705. DOI: 10.1016/j.ajo.2013.05.039.
36. Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema[J]. Ophthalmology, 2011, 118(4): 626-635. DOI: 10.1016/j.ophtha.2010.12.028.
37. Banerjee PJ, Quartilho A, Bunce C, et al. Slow-release dexamethasone in proliferative vitreoretinopathy: a prospective, randomized controlled clinical trial[J]. Ophthalmology, 2017, 124(6): 757-767. DOI: 10.1016/j.ophtha.2017.01.021.
38. Parodi MB, Iacono P, Petruzzi G, et al. Dexamethasone implant for macular edema secondary to ischemic retinal vein occlusions[J]. Retina, 2015, 35(7): 1387-1392. DOI: 10.1097/IAE.0000000000000492.
39. Querques L, Parravano M, Sacconi R, et al. Ischemic index changes in diabetic retinopathy after intravitreal dexamethasone implant using ultra-widefield fluorescein angiography: a pilot study[J]. Acta Diabetol, 2017, 54(8): 769-773. DOI: 10.1007/s00592-017-1010-1.
40. Noma H, Funatsu H, Mimura T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion[J]. Ophthalmology, 2009, 116(1): 87-93. DOI: 10.1016/j.ophtha.2008.09.034.
41. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders[J]. N Engl J Med, 1994, 331(22): 1480-1487. DOI: 10.1056/NEJM199412013312203.
42. Goel N, Kumar V, Ghosh B. Ischemic maculopathy following intravitreal bevacizumab for refractory diabetic macular edema[J]. Int Ophthalmol, 2011, 31(1): 39-42. DOI: 10.1007/s10792-010-9390-z.
43. Sabet-Peyman EJ, Heussen FM, Thorne JE, et al. Progression of macular ischemia following intravitreal bevacizumab[J]. Ophthalmic Surg Lasers Imaging, 2009, 40(3): 316-318.
44. Mansour AM, Bynoe LA, Welch JC, et al. Retinal vascular events after intravitreal bevacizumab[J]. Acta Ophthalmol, 2010, 88: 730-735. DOI: 10.1111/j.1755-3768.2009.01535.x.
45. Erol N, Gursoy H, Kimyon S, et al. Vision, retinal thickness, and foveal avascular zone size after intravitreal bevacizumab for diabetic macular edema[J]. Adv Ther, 2012, 29(4): 359-369. DOI: 10.1007/s12325-012-0009-9.
46. Manousaridis K, Talks J. Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease?[J]. Br J Ophthalmol, 2012, 96(2): 179-184. DOI: 10.1136/bjophthalmol-2011-301087.
47. Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase Ⅲ trials: RISE and RIDE[J]. Ophthalmology, 2013, 120(10): 2013-2022. DOI: 10.1016/j.ophtha.2013.02.034.
48. Ip MS, Domalpally A, Sun JK, et al. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy[J]. Ophthalmology, 2015, 122(2): 367-374. DOI: 10.1016/j.ophtha.2014.08.048.
49. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial[J]. JAMA, 2015, 314(20): 2137-2146. DOI: 10.1001/jama.2015.15217.
50. Sivaprasad S, Prevost AT, Vasconcelos JC, et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial[J]. Lancet, 2017, 389(10085): 2193-2203. DOI: 10.1016/S0140-6736(17)31193-5.
51. Arevalo JF, Maia M, Flynn HW Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy[J]. Br J Ophthalmol, 2008, 92(2): 213-216. DOI: 10.1136/bjo.2007.127142.
52. Lee SJ, Koh HJ. Enlargement of the foveal avascular zone in diabetic retinopathy after adjunctive intravitreal bevacizumab (avastin) with pars plana vitrectomy[J]. J Ocul Pharmacol Ther, 2009, 25(2): 173-174. DOI: 10.1089/jop.2008.0092.
53. Brown DM, Wykoff CC, Wong TP, et al. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis antiVEGF (RAVE) trial[J]. Retina, 2014, 34(9): 1728-1735. DOI: 10.1097/IAE.0000000000000191.
54. American Academy of Ophthalmology. Diabetic retinopathy Preferred Practice Pattern Guidelines[EB/OL].[2017-12-01] . https://www.aao.org/preferred-practice-pattern/diabetic-retinopathy-ppp-updated-2017.
55. Takamura Y, Tomomatsu T, Matsumura T, et al. The effect of photocoagulation in ischemic areas to prevent recurrence of diabetic macular edema after intravitreal bevacizumab injection[J]. Invest Ophthalmol Vis Sci, 2014, 55(8): 4741-4746. DOI: 10.1167/iovs.14-14682.
56. Tomomatsu Y, Tomomatsu T, Takamura Y, et al. Comparative study of combined bevacizumab/targeted photocoagulation vs bevacizumab alone for macular oedema in ischemic branch retinal vein occlusions[J]. Acta Ophthalmol, 2016, 94(3): 225-230. DOI: 10.1111/aos.12721.
57. Kernt M, Cheuteu R, Vounotrypidis E, et al. Focal and panretinal photocoagulation with a navigated laser (NAVILAS(R)[J]. Acta Ophthalmol, 2011, 89(8): 662-664. DOI: 10.1111/j.1755-3768.2010.02017.x.
58. Kozak I, Oster SF, Cortes MA, et al. Clinical evaluation and treatment accuracy in diabetic macular edema using navigated laser photocoagulator NAVILAS[J]. Ophthalmology, 2011, 118(6): 1119-1124. DOI: 10.1016/j.ophtha.2010.10.007.
59. Pei-Pei W, Shi-Zhou H, Zhen T, et al. Randomised clinical trial evaluating best-corrected visual acuity and central macular thickness after 532-nm subthreshold laser grid photocoagulation treatment in diabetic macular oedema[J]. Eye (Lond), 2015, 29(3): 313-321. DOI: 10.1038/eye.2015.1.
60. Lavinsky D, Cardillo JA, Melo LA Jr, et al. Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema[J]. Invest Ophthalmol Vis Sci, 2011, 52(7): 4314-4323. DOI: 10.1167/iovs.10-6828.
61. Chen G, Tzekov R, Li W, et al. Subthreshold micropulse diode laser versus conventional laser photocoagulation for diabetic macular edema: a meta-analysis of randomized controlled trials[J]. Retina, 2016, 36(11): 2059-2065. DOI: 10.1097/IAE.0000000000001053.
62. Sivaprasad S, Elagouz M, McHugh D, et al. Micropulsed diode laser therapy: evolution and clinical applications[J]. Surv Ophthalmol, 2010, 55(6): 516-530. DOI: 10.1016/j.survophthal.2010.02.005.